FB1006 is developed by Peking University Third Hospital.

What development phase is FB1006 in?

FB1006 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

FB1006

Peking University Third Hospital · FDA-approved active Small molecule Quality 4/100

FB1006, marketed by Peking University Third Hospital, is a small molecule with a key composition patent expiring in 2028. The drug's mechanism of interacting with specific biological pathways represents a unique therapeutic approach. The primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market adoption.

At a glance

Generic name	FB1006
Sponsor	Peking University Third Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FB1006 CI brief — competitive landscape report
FB1006 updates RSS · CI watch RSS
Peking University Third Hospital portfolio CI